A closer analysis of the NK cells in the samples obtained from AML patients treated with HDC plus IL-2 revealed an increase of two distinct subsets of CD56bright NK cells: CD56brightCD16neg and CD56brightCD16low cells (see representative dot plots in Figure 1A). Here, IL2 is linked to acute myeloid leukemia.